PTC Therapeutics, Inc. — 2016 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2016, filed March 16, 2017. PTC is a global biopharmaceutical company focused on RNA biology and rare diseases. Its only product revenue came from Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy (nmDMD), sold outside the United States through commercial markets and reimbursed early access programs. The filing also reports fourth-quarter results.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Net product revenue | $81.4 million | $33.7 million |
| Collaboration and grant revenue | $1.3 million | $3.1 million |
| Total revenue | $82.7 million | $36.8 million |
| Research and development expense | $117.6 million | $121.8 million |
| Selling, general and administrative expense | $97.1 million | $82.1 million |
| Operating loss | $132.1 million | $167.1 million |
| Net loss | $142.1 million | $170.4 million |
| Net loss per share, basic and diluted | $4.17 | $5.07 |
| Operating cash use | $103.6 million | $124.3 million |
- Revenue rose 125% year over year, principally from Translarna growth in existing markets and expansion into new territories. Product sales increased $47.8 million; collaboration and grant revenue declined $1.8 million.
- Operating expenses totaled $214.8 million. Lower R&D spending was more than offset by higher SG&A, which increased 18% amid commercial expansion and higher personnel costs. Net interest expense rose to $8.3 million, primarily reflecting a full year of interest on the convertible notes.
- Cash, cash equivalents and marketable securities were $231.7 million at year-end, down from $338.9 million. Working capital was $211.7 million, versus $310.6 million. Total assets were $269.3 million and stockholders’ equity was $119.6 million.
- Long-term debt carrying value was $98.2 million; the notes have $150 million principal, bear 3% cash interest, and mature August 15, 2022. Contractual obligations, including interest, totaled $177.0 million, with $4.5 million due within one year.
- Gross margin was not reported for 2016 because product costs were not yet expensed as cost of sales. Management said that, had cost of Translarna sold been expensed as cost of sales, gross margin would have exceeded 90%. PTC planned to capitalize commercial inventory and begin recognizing cost of goods sold from January 1, 2017.
- Fourth-quarter 2016 net product revenue was $25.1 million, operating loss was $25.0 million, and net loss was $26.8 million, compared with fourth-quarter 2015 net product revenue of $12.7 million and net loss of $50.9 million.
Material changes and notable events
- Translarna sales more than doubled from 2015, and the product was available in over 25 countries at year-end.
- R&D expense declined 3% year over year; SG&A increased 18%. A 2016 reorganization generated a one-time $2.5 million charge.
- The European Commission renewed Translarna’s conditional nmDMD marketing authorization in January 2017. It remains subject to annual review and the obligation to complete Study 041, with results due by the end of the third quarter of 2021. The authorization then in effect was scheduled to expire August 5, 2017, unless extended; a renewal request was submitted in February 2017.
- Following the failure of primary and secondary endpoints in the Phase 3 ACT CF trial, PTC announced in March 2017 that it would discontinue current nmCF development, close extension studies, and withdraw its EMA variation application.
- In the first quarter of 2017, PTC filed its Translarna U.S. NDA over protest after the FDA’s 2016 Refuse to File decision and denial of the company’s appeal. FDA set an October 24, 2017 target review date; approval remained uncertain.
- PTC entered an agreement in March 2017 to acquire all rights to Emflaza (deflazacort), an FDA-approved DMD treatment, for $140 million upfront—approximately $75 million cash and $65 million stock, subject to a share cap and cash make-whole. Additional sales-based payments and a potential $50 million milestone apply. The transaction was subject to closing conditions and was not reflected in the 2016 financial statements.
Outlook, risks and contingencies
- Management expected cash flows from product sales, existing cash and securities, and collaboration funding to cover operating and capital requirements for at least 12 months from the filing, while cautioning that assumptions could prove wrong. PTC expected continued significant operating losses and expenses and may need additional financing.
- Translarna’s revenue depends on annual renewal of its conditional EEA authorization, successful completion of Study 041, and sustainable country-by-country pricing and reimbursement. Failure to renew or material label restrictions could sharply reduce sales and access in multiple territories.
- The FDA’s concerns about the efficacy evidence for nmDMD, including the negative primary endpoint in ACT DMD and reliance on retrospective, subgroup and meta-analyses, create substantial U.S. approval risk and could require costly additional studies. Study 041 also carries enrollment, cost, execution and efficacy risks.
- Other pipeline programs include Translarna studies in nmMPS I, aniridia and Dravet syndrome/CDKL5; Roche-partnered SMA studies of RG7916; and the PTC596 cancer program. Roche’s prior SMA candidate RG7800 was terminated in December 2016. A $20 million Roche milestone would be triggered by commencement of the pivotal portion of either RG7916 study; PTC anticipated that both could advance during 2017.
- Commercialization faces reimbursement and price-control pressure, uneven order timing, foreign-exchange exposure, competition, and reliance on third-party manufacturers and distributors. The company reported no material effect from a hypothetical 10% currency move and no material interest-rate sensitivity in its short-duration investment portfolio.
- Three securities class-action cases were consolidated; defendants moved to dismiss in February 2017. PTC had not accrued a loss, stating liability was not probable or reasonably estimable. Management did not expect the matters to materially affect financial position or liquidity, though a period’s results could be affected.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal control were effective.
Important facts for investors to verify
- Current status of the annual EEA authorization renewal and progress, enrollment, costs and results for Study 041.
- FDA review outcome and any additional evidence or trials required for the nmDMD NDA.
- Translarna’s sales trajectory, reimbursement terms, sales allowances and cash collections, including concentration among distributors and country-level access.
- Cash burn, liquidity after the Emflaza transaction, acquisition funding and dilution, and the terms and timing of contingent payments.
- Convertible-note obligations, share-based compensation and potential equity dilution; confirm how cost of sales and gross margin are reported after the 2017 accounting change.
- Pipeline milestones and clinical outcomes, particularly RG7916 and the discontinued nmCF program, as well as the status of the securities litigation.